Homebased Medication Review: evaluation of homebased medication review by community pharmacists in elderly people: a randomised controlled trial
| ISRCTN | ISRCTN03155973 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN03155973 |
| Secondary identifying numbers | NTR1036 |
- Submission date
- 05/09/2007
- Registration date
- 05/09/2007
- Last edited
- 17/09/2008
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Other
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Dr A. Faber
Scientific
Scientific
SIR Institute for Pharmacy Practice and Policy
Leiden
2331 JE
Netherlands
| Phone | +31 (0)71 576 6157 |
|---|---|
| a.faber@stevenshof.nl |
Study information
| Study design | Multicentre, randomised, placebo-controlled, parallel group trial |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | GP practice |
| Study type | Quality of life |
| Scientific title | |
| Study objectives | An home-based medication review intervention conducted by a community pharmacists in close collaboration with the General Practitioner (GP) and patient improves the quality of pharmacotherapy in elderly patients. |
| Ethics approval(s) | Ethics approval received from the Medical Ethics Board of UMC Utrecht (University Medical Centre in Utrecht) (The Netherlands) on the 7th August 2007 (ref: 07-120/E; CCMO no.: 16412.041.07). |
| Health condition(s) or problem(s) studied | Home-based medication review |
| Intervention | A medication review will be performed by the patients pharmacist, using the medication list and GP clinical records. The medication review is evaluated and, if necessary, completed by an independent pharmacist panel. All potential drug related problems are identified and classified. The pharmacist visits the patient at home for an interview about the patient's medicines and to identify other possible drug related problems. The medication review will be completed using the information from the patient's interview. Adjustments in pharmacotherapy will be proposed and discussed with the patients GP. A treatment plan will be formulated. The GP or pharmacist will discuss the treatment plan with the patient. Patients in the control group receive regular care. |
| Intervention type | Other |
| Primary outcome measure | 1. The number of drug related problems per patient 2. The number of patients achieving target levels concerning blood pressure, cholesterol and HbA1C Outcomes will be measured at baseline (t = 0), and after 6 and 12 months after the intervention. |
| Secondary outcome measures | 1. The number of patient being treated optimally according to clinical guidelines 2. The number of medicines per patient 3. The number unplanned hospital admissions 4. Change in mean values for HBA1C, cholesterol level and/or blood pressure 5. Quality of life 6. Satisfaction of GPs, pharmacists and patient with the intervention 7. The capability of pharmacists to perform a comprehensive medication review Outcomes will be measured at baseline (t = 0), and after 6 and 12 months after the intervention. |
| Overall study start date | 01/09/2007 |
| Completion date | 01/09/2009 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Senior |
| Sex | Both |
| Target number of participants | 400 |
| Key inclusion criteria | 1. Persons aged 65 years or older 2. Prescribed five or more regular medicines, including at least one cardiovascular or anti-diabetic drug |
| Key exclusion criteria | Persons receiving repeat prescriptions solely from a specialist. |
| Date of first enrolment | 01/09/2007 |
| Date of final enrolment | 01/09/2009 |
Locations
Countries of recruitment
- Netherlands
Study participating centre
SIR Institute for Pharmacy Practice and Policy
Leiden
2331 JE
Netherlands
2331 JE
Netherlands
Sponsor information
Lloyds Apotheken (The Netherlands)
Industry
Industry
Postbus 191
Baarn
3740 AD
Netherlands
| info@lloydsapotheken.nl | |
| Website | http://www.lloydsapotheken.nl/ |
"ROR" |
https://ror.org/04ph6g561 |
Funders
Funder type
Industry
AstraZeneca (The Netherlands)
Government organisation / For-profit companies (industry)
Government organisation / For-profit companies (industry)
- Alternative name(s)
- AstraZeneca PLC, Pearl Therapeutics
- Location
- United Kingdom
Menzis Healthcare Insurance (Menzis Zorgverzekeraar) (The Netherlands)
No information available
Lloyds Apotheken (The Netherlands)
No information available
Achmea (The Netherlands)
No information available
Royal Dutch Pharmaceutical Society (Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie [KNMP]) (The Netherlands)
No information available
Results and Publications
| Intention to publish date | |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not provided at time of registration |
| Publication and dissemination plan | Not provided at time of registration |
| IPD sharing plan |
